Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
Harvard Business School
Moodys
Medtronic

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,911,214

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,911,214 protect, and when does it expire?

Patent 6,911,214 protects KALETRA and is included in one NDA.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,911,214
Title: Flavoring systems for pharmaceutical compositions and methods of making such compositions
Abstract:A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.
Inventor(s): Alani; Laman (Morris Plains, NJ), Gauwitz; Donald P. (McHenry, IL), Kaul; Dilip (Bridgewater, NJ), Lipari; John M. (Racine, WI), Ghosh; Soumojeet (Lindenhurst, IL), Marsh; Kennan C. (Lake Forest, IL), Whelan; Richard H. (Norfolk, MA), Petrossian; Vanik D. (Waban, MA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/946,085
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 6,911,214

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Medtronic
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.